Invivyd, Inc. - Common Stock, $0.0001 par value per share (IVVD)

CUSIP: 00534A102

Q1 2026 13F Holders as of 31 Mar 2026

Security type / class
Equity / Common Stock, $0.0001 par value per share
Total 13F shares
226,463,179
Total 13F value
$294,238,559
Holder snapshot 6 visible 7 signals
Share change
-14,508,842
Put/Call ratio
37%
SEC-reported price per share
$1.30
Number of holders
140
Value change
-$40,512,718
Number of buys
76
Open additional details 1 more signal available
Number of sells
41
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
304,892,029

Security key

00534A102

Report period

Q1 2026

Institutions

140

Top holders

10

IVVD full security history Ownership snapshot Full 13F holder table Previous quarter: Q4 2025 Invivyd, Inc. SEC filings Invivyd, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of IVVD - Invivyd, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
JANUS HENDERSON GROUP PLC
Disclosed value leader
Adimab, LLC
Comparable rows
15/15
Latest evidence
31 Dec 2025
13F 13D/G 3/4/5 Lead comparable stake: 12% 13D/G row: JANUS HENDERSON GROUP PLC Showing 1-6 of 15 holder rows.

Quick read

JANUS HENDERSON GROUP PLC leads the comparable SEC ownership view at 12%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens JANUS HENDERSON GROUP PLC's linked filing trail.
Comparable ownership Top 5
JANUS HENDERSON GROUP PLC 12%
BIOTECHNOLOGY VALUE FUND L P 9%
PERCEPTIVE ADVISORS LLC 7.9%
Adimab, LLC 7.3%
RA CAPITAL MANAGEMENT, L.P. 7%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
JANUS HENDERSON GROUP PLC
13F 13D/G
Company
13F 13D/G
12%
from 13D/G
$80,869,708
32,543,142 shares
 — 31 Dec 2025
BIOTECHNOLOGY VALUE FUND L P
13D/G
BVF PARTNERS L P/IL
13D/G
9%
$64,323,000
25,525,000 shares
 +$24,003,000 31 Dec 2025
PERCEPTIVE ADVISORS LLC
13F 13D/G
Company
13F 13D/G
7.9%
from 13D/G
$53,809,360
21,785,166 shares
 — 31 Dec 2025
Adimab, LLC
3/4/5 13D/G
10%+ Owner
3/4/5 13D/G
7.3%
from 13D/G
$85,667,229
21,687,906 shares
 — 19 Jan 2024
RA CAPITAL MANAGEMENT, L.P.
13F 13D/G
Company
13F 13D/G
7%
from 13D/G
$42,284,167
17,119,096 shares
 — 31 Dec 2025
MAVERICK CAPITAL LTD
13D/G 13F
Company
13D/G 13F
6.7%
$47,806,701
18,970,913 shares
 +$22,029,323 31 Dec 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
140
Shares
226,463,179
Rows available
140
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2026 vs Q4 2025 Across Filers

Q4 2025 holders
115
Q1 2026 holders
140
Holder diff
25
Investor Q4 2025 Shares Q1 2026 Shares Share Diff Share Chg % Q4 2025 value Q1 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .